A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. 1998

S Shichijo, and M Nakao, and Y Imai, and H Takasu, and M Kawamoto, and F Niiya, and D Yang, and Y Toh, and H Yamana, and K Itoh
Department of Immunology, Kurume University School of Medicine, Kurume, Japan.

Except for melanomas, tumor antigens recognized by cytotoxic T lymphocytes (CTLs) are yet unidentified. We have identified a gene encoding antigenic peptides of human squamous cell carcinomas (SCCs) recognized by human histocompatibility leukocyte antigens (HLA)- A2601-restricted CTLs. This gene showed no similarity to known sequences, and encoded two (125- and 43-kilodalton [kD]) proteins. The 125-kD protein with the leucine zipper motif was expressed in the nucleus of the majority of proliferating cells tested, including normal and malignant cells. The 43-kD protein was expressed in the cytosol of most SCCs from various organs and half of lung adenocarcinomas, but was not expressed in other cancers nor in a panel of normal tissues. The three nonapeptides shared by the two proteins were recognized by the KE4 CTLs, and one of the peptides induced in vitro from peripheral blood mononuclear cells (PBMCs) the CTLs restricted to the autologous tumor cells. The 43-kD protein and this nonapeptide (KGSGKMKTE) may be useful for the specific immunotherapy of HLA-A2601(+) epithelial cancer patients.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D006680 HLA Antigens Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases. Human Leukocyte Antigen,Human Leukocyte Antigens,Leukocyte Antigens,HL-A Antigens,Antigen, Human Leukocyte,Antigens, HL-A,Antigens, HLA,Antigens, Human Leukocyte,Antigens, Leukocyte,HL A Antigens,Leukocyte Antigen, Human,Leukocyte Antigens, Human
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S Shichijo, and M Nakao, and Y Imai, and H Takasu, and M Kawamoto, and F Niiya, and D Yang, and Y Toh, and H Yamana, and K Itoh
January 2002, Journal of immunotherapy (Hagerstown, Md. : 1997),
S Shichijo, and M Nakao, and Y Imai, and H Takasu, and M Kawamoto, and F Niiya, and D Yang, and Y Toh, and H Yamana, and K Itoh
February 1991, The Journal of biological chemistry,
S Shichijo, and M Nakao, and Y Imai, and H Takasu, and M Kawamoto, and F Niiya, and D Yang, and Y Toh, and H Yamana, and K Itoh
September 1999, Journal of immunology (Baltimore, Md. : 1950),
S Shichijo, and M Nakao, and Y Imai, and H Takasu, and M Kawamoto, and F Niiya, and D Yang, and Y Toh, and H Yamana, and K Itoh
August 2002, Japanese journal of cancer research : Gann,
S Shichijo, and M Nakao, and Y Imai, and H Takasu, and M Kawamoto, and F Niiya, and D Yang, and Y Toh, and H Yamana, and K Itoh
April 2006, International journal of cancer,
S Shichijo, and M Nakao, and Y Imai, and H Takasu, and M Kawamoto, and F Niiya, and D Yang, and Y Toh, and H Yamana, and K Itoh
June 1996, The Journal of experimental medicine,
S Shichijo, and M Nakao, and Y Imai, and H Takasu, and M Kawamoto, and F Niiya, and D Yang, and Y Toh, and H Yamana, and K Itoh
December 1991, Science (New York, N.Y.),
S Shichijo, and M Nakao, and Y Imai, and H Takasu, and M Kawamoto, and F Niiya, and D Yang, and Y Toh, and H Yamana, and K Itoh
March 2007, Journal of immunology (Baltimore, Md. : 1950),
S Shichijo, and M Nakao, and Y Imai, and H Takasu, and M Kawamoto, and F Niiya, and D Yang, and Y Toh, and H Yamana, and K Itoh
August 1988, Nature,
S Shichijo, and M Nakao, and Y Imai, and H Takasu, and M Kawamoto, and F Niiya, and D Yang, and Y Toh, and H Yamana, and K Itoh
January 1997, Cancer research,
Copied contents to your clipboard!